– Dell CIO to Lead Biogen Idec’s IT and Technology Innovation Initiatives –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) today announced the appointment of Adriana (Andi) Karaboutis as executive vice president, Technology and Business Solutions, effective September 24, 2014. She will report directly to the company’s chief executive officer, George Scangos, Ph.D., and will be a member of the Biogen Idec management team.
Ms. Karaboutis will lead Biogen Idec’s information technology (IT) operations and advance the company’s use of technology and data to enhance overall engagement with patients and healthcare providers. In this new role, she will drive technology initiatives throughout the entire organization, leading Biogen Idec’s efforts to leverage advanced analytics to inform the drug discovery process, unlock new insights from clinical data and improve patient care through tools such as wearable and ingestible devices.
“Andi is a remarkable technology leader who will enable Biogen Idec to infuse digital innovation at all levels of our business and research organizations,” said Dr. Scangos. “As the pace of digital innovation accelerates, Andi will play a critical role in our mission to improve human health and support those who serve patients. She views data and information as a new currency to gain insights, tailor conversations, improve research and achieve business goals.”
Ms. Karaboutis joins Biogen Idec from Dell where she was vice president and chief information officer (CIO), with responsibility for the company’s overall IT enterprise and customer experience. Her background also includes leadership roles in global IT and business operations at Ford Motor Company and General Motors. Ms. Karaboutis received a bachelor’s of science (B.S.) in Computer Science as a Merit Scholar from Wayne State University and has completed the accelerated Marketing Strategy Program at Duke University’s Fuqua School of Business.
About Biogen Idec
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the Company, please visit www.biogenidec.com.